The present invention provides compounds of formula I ##STR00001## and
pharmaceutically acceptable salts thereof.The formula I compounds inhibit
the tyrosine kinase activity of growth factor receptors such as VEGFR-2,
FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer
agents. The formula I compounds are also useful for the treatment of
other diseases associated with signal transduction pathways operating
through growth factor receptors.